We are pleased to share a community update from Denali Therapeutics regarding their investigational program in Pompe disease.
Denali has officially begun recruitment for its clinical study evaluating DNL952 in adults living with Late-Onset Pompe Disease (LOPD). DNL952 is an investigational enzyme replacement therapy (ERT) designed using Denali’s Transport Vehicle™ platform to reach both muscle tissue and the brain.
For full details regarding the study objectives, locations, and participant eligibility, please read the full community letter below:
📄 Denali Therapeutics Update Late-onset Pompe Disease Study (PDF)
Additional trial details and recruiting site locations can also be found on ClinicalTrials.gov (Identifier: NCT07354724). For direct inquiries, you can reach Denali’s Patient Advocacy team at patientadvocacy@dnli.com.